BioInvent To Cut Jobs By A Quarter Following Head-To-Head Clinical Trial Disappointment
This article was originally published in The Pink Sheet Daily
Executive Summary
Sweden's antibody platform company BioInvent moves quickly to reorganize following disappointing Phase IIb clinical results with a potential antithrombotic antibody.